Oncolytic virotherapy using coxsackie virus

Share :
Published: 10 Oct 2016
Views: 2501
Dr Hardev Pandha - University of Surrey, Guildford, UK

Dr Pandha speaks with ecancertv at ESMO 2016 about two trials of coxsackie virus as an immune modulator.

Oncolytic virotherapy is discussed more broadly in an ecancer review here.

Dr Pandha describes results from the CANON trial of virotherapy for bladder cancer, and the STORM / KEYNOTE200 trial which combined virotherapy with immune modulator pembrolizumab.

He describes how viral stimulation of immune activity, further enhanced by checkpoint inhibitors, can have significant outcomes, and considers wider adoption of virotherapy to complement other treatment modalities.